CC at a glance
Chemours Co (CC, SEC CIK 1627223) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 10, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Chemours Co (CC) reported revenue of $5.8 billion (up 0.4% from FY2024) and a net loss of $386.0 million. Diluted EPS was -$2.57.
- As of June 30, 2026, 37 institutional investment managers tracked by SignalX reported holding Chemours Co (CC) shares worth $1.5 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Familiar Calderon Gerardo on August 12, 2026 of 1,935 shares at $15.53 per share.
- In the last 90 days, CC insiders reported 7 open-market purchases ($489K) and 0 open-market sales ($0) on Form 4, a net purchase of $489K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $5.8B
- +0.4% vs prior year
- Insiders · 90 days
- 7 buys · 0 sells
- Net +$489K
- 13F holders
- 37 funds
- $1.5B · +1 vs prior quarter
- Latest 8-K
- Sep 10, 2026
- Item 1.01 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- Litigation risk: $270 million settlement charge with State of New Jersey for environmental litigation in 2025
- Geopolitical risk: Sale of Taiwan Titanium site for $360 million pending local regulatory and environmental approvals, mid-2026
- Operational risk: Washington Works fluoropolymer plant outage caused $20-$25 million Q1 2026 earnings impact due to utility disruption and winter weather
- Competitive risk: Titanium Technologies mine idled in Florida, shifting to third-party contractor to reduce costs and improve cash flow
- Financial risk: $1.05 billion senior secured term loan maturity extended to October 2032 with adjusted SOFR +3.5% margin
Management Discussion & Analysis
- Revenue $5.758B, down 2% YoY; Thermal & Specialized Solutions up $236M (13%) to $2.1B, Titanium Technologies down $143M (6%) to $2.4B, Advanced Performance Materials down $63M (5%) to $1.3B
- Profitability: Thermal & Specialized Solutions Adj. EBITDA margin 32% vs 31%, Titanium Technologies margin 6% vs 12%, Advanced Performance Materials margin 9% vs 12%
- Best segment: Thermal & Specialized Solutions Adj. EBITDA $670M, up 17%; Worst segment: Titanium Technologies Adj. EBITDA $145M, down 52%
- Cash flow & capital: $670M cash ($447M foreign), Revolving Credit Facility availability $955M, Corporate expenses down $75M to $181M, Supply chain financing accelerated $414M receivables collections with $6M discount
- Outlook/risks: Tax Act impact under ongoing review, operational disruption risks (rail and shutdowns), Moody's Ba3 rating negative outlook, liquidity expected adequate through Feb 2027
Business Overview
- Core business: global provider of performance chemicals serving diverse industries via three segments; Thermal & Specialized Solutions, Titanium Technologies, Advanced Performance Materials
- New strategy "Pathway to Thrive" launched in 2024 focusing on operational excellence, growth in data center cooling, next-gen refrigerants, and semiconductor fabrication
- Strategic shift toward portfolio management emphasizing higher-margin, higher-growth applications and optimizing asset footprint
- Approximately 2,400 customers served in ~110 countries via 28 production facilities across 8 countries
- Titanium Technologies segment advancing "Transformation Plan" to become one of lowest-cost, high-quality TiO2 pigment producers
AI summary of the CC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New regulatory risk: ECHA RAC recommended TFA as Reproductive Toxicity Category 1B and PMT/vPvM substance in June 2026
- Most material update: EU PFAS restriction evaluation now targets committee opinions by end-2026, with earliest restrictions in 2027
- Legal and compliance exposure: Fayetteville Consent Order remedies, including barrier wall and groundwater extraction, may exceed recorded reserves
- Operational risk: PFAS regulations could restrict product market access, trigger plant changes, or cause production interruptions
- Financial risk: Environmental liabilities may increase if U.S. PFAS drinking-water standards and CERCLA designations withstand court challenges
AI summary of the CC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- $455M North Carolina PFAS settlement payable over 15 years, resolving facility and unrelated contamination claims
- Chemours responsible for 50%, implying $227.5M of nominal payments under the agreement
Item 7.01: Regulation FD Disclosure
- Chemours press release dated September 10, 2026 covers PFAS-related cost-sharing arrangements with Corteva and DuPont
- Investor focus: potential future PFAS liabilities, remediation costs, litigation exposure, and liquidity impact
Item EX-99.1: Item EX-99.1
- $455 million settlement over 15 years resolves North Carolina PFAS litigation involving Fayetteville Works and AFFF claims
- Chemours’ 50% share approximately $180 million on a net present value basis, covered by existing accruals
Item EX-99.1: Item EX-99.1
- Investor presentation highlights $5.8B trailing-twelve-month sales and $733M adjusted EBITDA through June 30, 2026
- Management targets adjusted EBITDA above $1B by 2027, versus $742M in 2025
Item 7.01: Regulation FD Disclosure
- Investor presentation posted September 9, 2026 for upcoming meetings with investors, analysts and other interested parties
- Presentation available through Chemours’ Investor Relations website and furnished as Exhibit 99.1
Item 2.02: Results of Operations and Financial Condition
- Chemours issued Q2 2026 financial results on August 4, 2026
- Investor presentation scheduled by 8:00 a.m. EDT August 5, 2026, ahead of the conference call
Item EX-99.1: Item EX-99.1
- Q2 sales $1.591B, down 1% YoY as 4% volume decline offset 2% pricing gains
- Adjusted EBITDA $247M, down 5%; APM weakness and Washington Works outage costs outweighed pricing benefits
AI summaries of CC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CC
Don't miss the next CC filing
- Alerts as it files. A push when CC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CC, by share count.
- Ask anything. An AI agent that reads every CC filing and answers with sources.
CC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MATHER COURTNEY | A | Sep 30, 2026 | 2,118 | $13.57 |
| Familiar Calderon Gerardo | Buy | Aug 12, 2026 | 1,935 | $15.53 |
| Will David | F | Aug 12, 2026 | 2,426 | $15.24 |
| Dignam Denise | Buy | Aug 11, 2026 | 3,378 | $14.95 |
| Martinko Joseph T. | Buy | Aug 7, 2026 | 1,939.801 | $15.47 |
| CRANSTON MARY B | Buy | Aug 7, 2026 | 6,000 | $15.82 |
| Foley Michael Robert | Buy | Aug 7, 2026 | 1,934.231 | $15.51 |
| Cowan Alister | Buy | Aug 7, 2026 | 13,000 | $15.62 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $5.8B | $5.8B |
| Gross Profit | $1.3B | $1.2B | $902.0M |
| Net Income | - | $86.0M | -$386.0M |
| Gross Margin | - | 19.9% | 15.5% |
| Net Margin | - | 1.5% | -6.6% |
| Balance Sheet | |||
| Total Assets | $8.3B | $7.5B | $7.4B |
| Equity | - | $604.0M | $250.0M |
| ROE | - | 14.2% | -154.4% |
| Per Share | |||
| EPS | $-1.60 | $0.57 | $-2.57 |
| Cash Flow | |||
| Operating CF | - | -$633.0M | $264.0M |
| CapEx | $370.0M | $360.0M | $213.0M |
Source: XBRL data in Chemours Co (CC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 37 | $1.54B |
| Q1 2026 | 36 | $1.65B |
| Q4 2025 | 34 | $1.00B |
| Q3 2025 | 33 | $1.43B |
| Q2 2025 | 32 | $997.5M |
| Q1 2025 | 30 | $880.5M |
| Q4 2024 | 26 | $860.6M |
| Q3 2024 | 22 | $361.5M |
- BlackRock+897.2K (+4%)
- Dimensional Fund Advisors+537.1K (+24%)
- JPMorgan Chase & Co+398.5K (+10%)
- Two Sigma Investments+367.7K (+37%)
- Vanguard Portfolio Management LLC+243.5K (+2%)
- Bank of America Corp−744.7K (-57%)
- FMR LLC (Fidelity)−518.0K (-61%)
- Goldman Sachs Group−461.7K (-15%)
- Wells Fargo & Co−309.0K (-60%)
- Citadel Advisors LLC−271.0K (-95%)
- Blackstone Group+66.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 250 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 1, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - |
Related Materials companies
- BCPC · BALCHEM CORPChemicals & Allied Products
- ECVT · Ecovyst Inc.Chemicals & Allied Products
- FMC · Fmc CorpChemicals & Allied Products
- HUN · Huntsman CORPChemicals & Allied Products
- NGVT · Ingevity CorpChemicals & Allied Products
- IOSP · INNOSPEC INC.Chemicals & Allied Products
- AEM · Agnico Eagle Mines LtdGold and Silver Ores
- APD · Air ProductsIndustrial Inorganic Chemicals
CC SEC filings: frequently asked questions
Are CC insiders buying or selling?
In the last 90 days, Chemours Co (CC) officers, directors and 10% owners reported 7 open-market purchases worth $488,619 by 7 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CC stock?
As of June 30, 2026, the largest Chemours Co (CC) holders among the 13F filers tracked by SignalX were BlackRock ($477.8 million), Vanguard Portfolio Management LLC ($216.9 million), Vanguard Capital Management LLC ($139.2 million), State Street Corp ($125.5 million), Ameriprise Financial ($101.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Chemours Co (CC) reported revenue of $5.8 billion (up 0.4% from FY2024) and a net loss of $386.0 million. Diluted EPS was -$2.57. The figures come from the XBRL data in the 10-K.
What are the main risks in CC's latest 10-K?
In the 10-K filed February 24, 2026, Chemours Co (CC) flagged: Litigation risk: $270 million settlement charge with State of New Jersey for environmental litigation in 2025. Geopolitical risk: Sale of Taiwan Titanium site for $360 million pending local regulatory and environmental approvals, mid-2026. (AI summary of the Risk Factors section.)
What did CC report in its latest 8-K?
Chemours Co (CC) filed an 8-K on September 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 7.01 (Regulation FD Disclosure). $455M North Carolina PFAS settlement payable over 15 years, resolving facility and unrelated contamination claims.
What are the latest CC SEC filings?
Chemours Co (CC) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 10, 2026 and a Form 4 insider filing on October 1, 2026.
What is CC's SEC CIK number?
Chemours Co (CC)'s SEC Central Index Key (CIK) is 1627223. EDGAR lists every CC filing under that number.
Ask anything about CC
The research agent reads CC's filings, financials, insider trades and 13F holders, then answers with sources.